摘要
目的:观察干扰素-α联合化疗治疗恶性黑色素瘤的临床疗效及不良反应。方法:对25例晚期恶性黑色素瘤患者采用干扰素联合氮烯咪胺(DTIC)为主的DDAVC方案化疗(治疗组),25例晚期恶性黑色素瘤患者采用DDVAC方案化疗(对照组),比较两组的近期疗效、不良反应、免疫水平以及生存时间。结果:治疗组有效率为64%,对照组为36%,治疗组显著优于对照组(P<0.05)。经干扰素-α免疫治疗的患者化疗一周后免疫水平继续提高,而单纯化疗的患者一周后明显下降,两者之间对比有显著差异(P<0.05)。治疗组化疗不良反应低于对照组。两组的生存时间差异有统计学意义(P<0.05)。结论:干扰素-α联合氮烯咪胺(DTIC)为主的DDAVC方案化疗可取得较满意的疗效。
Objective：To study the therapeutic effect of interferon -αcondined with chemotherapy for malignant melanoma. Methods： Twenty five advanced malignant melanoma patients was treatid by interferon alpha combined with chemotherapy that was consisted of dacarbazine（ DTIC）, chlorethyl （CCNU）, adriamycin （ADM）or pharmorubi- cin（EPI） ,vinblastine （ VCR）, cisplatin （DDP） （ DDVAC program） as curative group, 25 advanced melanoma was treated with chemotherapy that was consisted of dacarbazine （ DTIC）, chlorethyl （ CCNU）, adriamycin （ADM） or phar- morubicin （ EPI）, vinblastine （ VCR）, cisplatin （DDP） （ DDVAC program） as compared group. Results ： The response rates to chemotherapy in curative and compared groups were 64% and 36% respectively （P 〈 0.05 ）, immune level of patients treated with interferon alpha combined with chemotherapy continued to invrease ,inversely, immune level of patients treated with pure chemotherapy decreased obviously,the difference was significant. The survival time was sig- nificant different between curative group and compared group. Conclusion： Interferon alpha combined with chemotherapy consisted of dacarbazine （DTIC）, chlorethyl （CCNU）, adriamycin （ADM）or pharmorubicin （EPI）, vinblastine （VCR）, cisplatin（DDP） （DDVAC program）can obtain satisfied therapeutic effect.
出处
《现代肿瘤医学》
CAS
2009年第1期112-114,共3页
Journal of Modern Oncology
关键词
干扰素-Α
联合化疗
晚期恶性黑色素瘤
interferon alpha
combined chemotherapy
advanced malignant melanoma
